|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
FDA Issues Approvable Letter For Alkermes (ALKS)' VIVITROL(TM) (Formerly VIVITREX(R)), For The Treatment Of Alcohol Dependence
12/28/2005 6:36:44 PM
CAMBRIDGE, Mass.& FRAZER, Pa.--(BUSINESS WIRE)--Dec. 28, 2005--Alkermes, Inc. (Nasdaq: ALKS) and Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) issued an approvable letter for VIVITROL(TM) (naltrexone for extended-release injectable suspension), which is under review for the treatment of alcohol dependence in combination with a treatment program that includes psychosocial support. The New Drug Application (NDA) for VIVITROL, formerly known as VIVITREX(R), was submitted on March 31, 2005. Alkermes and Cephalon continue to prepare for the launch of VIVITROL during the second quarter of 2006.
|
|
|
|
|
|
|
|
|
|
|